Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Profit After Tax: 2012-2024

Historic Profit After Tax for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to -$56.4 million.

  • Theravance Biopharma's Profit After Tax rose 128.47% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year increase of 159.40%. This contributed to the annual value of -$56.4 million for FY2024, which is 2.22% down from last year.
  • Latest data reveals that Theravance Biopharma reported Profit After Tax of -$56.4 million as of FY2024, which was down 2.22% from -$55.2 million recorded in FY2023.
  • Theravance Biopharma's Profit After Tax's 5-year high stood at $872.1 million during FY2022, with a 5-year trough of -$294.8 million in FY2020.
  • In the last 3 years, Theravance Biopharma's Profit After Tax had a median value of -$55.2 million in 2023 and averaged $253.5 million.
  • As far as peak fluctuations go, Theravance Biopharma's Profit After Tax spiked by 429.02% in 2022, and later plummeted by 106.33% in 2023.
  • Theravance Biopharma's Profit After Tax (Yearly) stood at -$294.8 million in 2020, then increased by 10.09% to -$265.1 million in 2021, then skyrocketed by 429.02% to $872.1 million in 2022, then slumped by 106.33% to -$55.2 million in 2023, then fell by 2.22% to -$56.4 million in 2024.